Part of a public/private partnership, the U.S. Military HIV Research Program (MHRP), centered at WRAIR, is collaborating on studies in Maputo,
Beira and Chokwe that will expand research capacity and inform future HIV vaccine research in this region of Africa.
In Mozambique, MHRP is conducting research in partnership with the National Ministry of Health/National Institute of Health,
the Catholic University of Mozambique and FHI360. These collaborative efforts will advance HIV research by helping scientists better
understand the HIV epidemic in Mozambique and increase capacity in the country to perform future HIV vaccine trials.
Expansion of research activities into Mozambique allows MHRP researchers the opportunity to test future vaccine
candidates against the predominant HIV subtype (C) circulating in this part of the world.
MHRP is assisting the National Institute of Health at its research centre in Maputo, which is testing an MVA vaccine developed
by MHRP and the Laboratory of Viral Diseases/NIAID. MHRP is providing the MVA, which is delivered after initial vaccination with a DNA vaccine
developed by the Karolinska Institute in Sweden. In addition, MHRP provides GCP monitoring of this clinical trial.
Additionally, MHRP is assisting with research that serves as the screening phase for a prospective cohort
study to better understand the area's HIV prevalence, incidence and follow-up rates. MHRP is funding a study at the Chokwe Health
Research and Training Center, an affiliate of the Mozambique National Institute of Health and assisting with follow-up studies and data
analysis for a study at the Center for Infectious Disease Research in Beira.